Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
149 people get PTX articles and Market Currents by email alert.
Get email alerts on PTX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
5 Undervalued Healthcare Stocks With Positive Receivables TrendsKapitall • Thu, Apr 12, 2012
-
20 Healthcare Stocks With Strong Sales TrendsKapitall • Thu, Dec 1, 2011
-
-
-
Business Wire (May 10, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Mar 6, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Jan 28, 2013)
-
Business Wire (Jan 24, 2013)
-
Business Wire (Jan 17, 2013)
-
Business Wire (Jan 2, 2013)
-
GlobeNewswire (Dec 11, 2012)
-
Business Wire (Dec 11, 2012)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Aug 24, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
PTX vs. ETF Alternatives
Company Description
Currently, there's no company description for PTX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 2:16 PM Shares of Pernix Therapeutics (PTX -5.6%) hits a new 52-week low today, continuing its downtrend following a disappointing Q1 report last week. Additionally, Cantor cut its price target on the stock to $3 from $7, citing concerns that the company could take a year or so to stabilize following the appointment of new CEO Mike Pearce. Comment! [Healthcare, Earnings, On the Move]
- Friday, May 10, 9:05 AM Pernix Therapeutics (PTX): Q1 EPS of -$0.23 misses by $0.22. Revenue of $22.1M misses by $5.91M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Monday, March 18, 12:48 PM
Midday top 10 gainers: YRCW +25%. PRWT +22%. ULTR +17%. IG +17%. CHYR +16%. ATOS +14%. TA +13%. NYMX +13%. WILC +11%. SORL +11%.
Midday top 10 losers: AMBO -19%. PTX -12%. SOL -10%. CNET -10%. EMITF -9%. TSEM -8%. MNDO -8%. RGDX -8%. JVA -8%. AMBA -8%. 1 Comment [On the Move] - Monday, March 18, 8:11 AM Pernix Therapeutics (PTX): Q4 EPS of -$0.05 misses by $0.07. Revenue of $18.2M misses by $4.24M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 28, 11:40 AM Pernix Therapeutics (PTX -2.6%) slips this morning, despite its announcement that its Hawthorn Pharmaceuticals unit has received FDA approval for Vituz, a prescription medication for coughs and colds. The company also said its Cypress Pharmaceuticals unit got final FDA approval for Mefenamic Acid Capsules, a generic version of Ponstel, for relief of mild-to-moderate pain in patients 14 years of age and older and the treatment of primary dysmenorrhea. Comment! [Healthcare, On the Move]
- Thursday, February 28, 9:35 AM Pernix (PTX +4.2%) unit Hawthorn receives FDA approval for its Vitus drug for treating adults with coughs, colds and symptoms associated with upper respiratory allergies. Pernix's Cypress receives approval for a generic version of Ponstel Capsules for pain relief and treating primary dysmenorrhea (cramp in the lower abdomen in women). (PR) Comment! [On the Move, Healthcare]
- Tuesday, December 11, 2012, 9:10 AM Somaxon Pharmaceuticals (SOMX) +103.4% premarket after agreeing to be acquired by Pernix Therapeutics (PTX) in a stock-for-stock transaction valued at $25M. Comment! [Healthcare, M&A, On the Move]
- Wednesday, November 14, 2012, 8:11 AM Pernix Therapeutics (PTX): Q3 EPS of -$0.01 misses by $0.04. Revenue of $18.1M (+6.3% Y/Y) beats by $3.1M. (PR) Comment! [Earnings, Healthcare]
-
Thursday, April 26, 2012, 9:20 AM
Premarket gainers: PATK +26%. HTWR +15%. REGN +14%. NUAN +14%. LOGI +14%. VHC +12%. CTXS +12%. NRGY +10%. EQIX +9%. CRUS +8%. SPPI +8%. INCY +7%. XLNX +7%. WPI +7%. AMRN +5%. EA +7%. MWW +5%. AH +6%. PHM +6%. AIS +5%. AIXG +5%. LSI +4%. TS +3%. UN +3%. ZNGA +3%. FRO +3%. RDS +3%.
Losers: FURX -28%. PCS -15%. HRB -15%. TQNT -14%. ALU -13%. TSPT -12%. AET -9%. PTX -7%. AKAM -6%. AZN -6%. ZMH -5%. DB -5%. HERO -5%. STD -5%. DOW -4%. CELG -4%. CS -4%. CROX -4%. GG -3%. BWA -3%. UNH -3%. LVS -3%. VALE -3%. UPS -3%. POT -3%. Comment! [On the Move] - Tuesday, August 16, 2011, 10:52 AM Specialty pharmaceutical developer Pernix Therapeutics (PTX +18%) takes off after Q2 earnings easily beat expectations. Revenues leapt 178% Y/Y to $12M, easily topping analyst estimates for $7.1M, on record sales of its CEDAX formulation and improvement from its generic product line. Comment! [Healthcare, On the Move]
- Friday, August 12, 2011, 11:10 AM Permix Therapeutics (PTX +5.7%) trades higher this morning after being initiated with a buy at Stifel Nicolaus. The firm says its "a classic growth story," with a "proven acquistition strategy to fuel expansion." Comment! [Healthcare, On the Move]
-
Asif Suria
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc. $SOMX $PTX http://bit.ly/T4Vk7V - View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
PTX - 40% Barchart sell signal-Below 20 & 50 day moving averages-21.89% off high-Relative Strength Index 40.74% and falling - View all 0 replies
-
Jim Van Meerten
PTX -Perrix Pharma-100% Barchart technical buy signal 16new highs and up 19.47% in the last month- Relative Strength Index 68.32% and rising - View all 0 replies
-
Jim Van Meerten
PTX - Golf Trust of America - 00% Barchart buy signal-16 new highs and up 21.33% in the last month-Relative Strength Index 69.69% and rising - View all 0 replies
LATEST REPLIES